CD25/71 allodepleted donor T-cell therapy (UCL/MRC)

N/A

Report date: 2025/01/02 16:12:12

Base Information

Drug NameCD25/71 allodepleted donor T-cell therapy (UCL/MRC)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity College London Medical Research Council

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUniversity College London Medical Research Council

Active IndicationsN/A

Inactive IndicationsHematologic Neoplasms

Other Information

ATC CodeN/A